Pfizer Stock Sees Revision in Evaluation Amid Recent Performance Decline

Pfizer Ltd., a leading entity in the pharmaceuticals and drugs sector, has recently undergone an adjustment in its evaluation, reflecting the challenges it has faced in the market. On December 20, 2024, the stock experienced a decline of -3.74%, which is notably more significant than the sector's decrease of -3.24%. This downturn is part of a broader trend, as Pfizer's stock has seen consecutive losses over the past two days, totaling -4.49%.
On this particular trading day, the stock reached an intraday low of Rs 4806.9, indicating a decrease of -3.97%. Furthermore, Pfizer's stock is currently trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, suggesting a persistent downward trajectory.

In the context of the overall market, Pfizer's one-day decline stands in stark contrast to the Sensex, which only fell by -1.16%. Over the past month, Pfizer's stock has decreased by -7.43%, while the Sensex has managed a slight increase of 0.93%. Amid these fluctuations, Pfizer has been added to MarketsMOJO's list, highlighting its ongoing relevance in the market despite recent challenges. The stock's call remains a 'Hold' according to MarketsMOJO, indicating a cautious approach as investors navigate the current landscape.